NCT01646671View on ClinicalTrials.gov

Safety and Tolerability and Efficacy of LCZ696 in Japanese Severe Hypertensive Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions
Severe Hypertension
Interventions
DRUG

LCZ696

LCZ696 200 mg tablet once daily

DRUG

LCZ696

2 tablets of LCZ696 200 mg once daily titrated up from 1 tablet of 200 mg once daily

DRUG

LCZ696

2 tablets of LCZ696 200 mg once daily titrated up from 1 tablet of 200 mg once daily plus other HTN medications

Trial Locations (9)

231-0023

Novartis Investigative Site, Yokohama

606-8507

Novartis Investigative Site, Kyoto

113-0031

Novartis Investigative Site, Bunkyo-ku

192-0918

Novartis Investigative Site, Hachiōji

105-7390

Novartis Investigative Site, Minato-ku

108-0075

Novartis Investigative Site, Minato-ku

143-0023

Novartis Investigative Site, Ōta-ku

150-0002

Novartis Investigative Site, Shibuya-ku

141-0032

Novartis Investigative Site, Shinagawa-ku

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY